Maxim Group Reaffirms “Hold” Rating for Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON)‘s stock had its “hold” rating reaffirmed by equities research analysts at Maxim Group in a report issued on Friday,Benzinga reports.

Separately, Ascendiant Capital Markets decreased their target price on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a report on Wednesday, November 27th.

Aclarion Price Performance

Shares of Aclarion stock traded down $0.01 during trading hours on Friday, reaching $0.11. The company had a trading volume of 582,912 shares, compared to its average volume of 1,414,292. Aclarion has a one year low of $0.11 and a one year high of $7.40. The business has a fifty day simple moving average of $0.18 and a 200 day simple moving average of $0.23.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.